Stockscreener 앱 받기
4.10
2.24%
0.09
시간 외 거래:
4.10
전일 마감가:
$4.01
열려 있는:
$4
하루 거래량:
644.14K
Relative Volume:
0.70
시가총액:
$288.05M
수익:
-
순이익/손실:
$-96.66M
주가수익비율:
-1.907
EPS:
-2.15
순현금흐름:
$-83.73M
1주 성능:
+0.49%
1개월 성능:
-12.95%
6개월 성능:
-29.91%
1년 성능:
-65.83%
1일 변동 폭
$3.90
$4.17
1주일 범위
$3.89
$4.29
52주 변동 폭
$2.86
$16.62
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
OLMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
4.10 | 288.05M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Deeper Dive: Understanding Olema Pharmaceuticals Inc (OLMA) Through its Various Ratios - DWinneX
Olema Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Two Sigma Investments LP Has $425,000 Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Squarepoint Ops LLC Grows Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
HC Wainwright Issues Pessimistic Outlook for OLMA Earnings - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Wellington Management Group LLP - MarketBeat
Jane Street Group LLC Trims Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Q2 EPS Forecast for Olema Pharmaceuticals Lowered by Analyst - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Purchases 3,298 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Olema Oncology Expands Team with 322,000 Share Options Grant to New Biotech Talent - Stock Titan
Deutsche Bank AG Increases Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Bank of America Corp DE Has $5.05 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Millennium Management LLC Acquires 901,159 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance - MSN
H.C. Wainwright maintains Buy on Olema Pharma, $28 target By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Cuts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Ameriprise Financial Inc. Has $2.62 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. Announces Palazestrant Dose Selection and Trial-In-Progress Poster at ASCO 2025 Annual Meeting - marketscreener.com
Olema Pharmaceuticals (OLMA) Aligns with FDA on Key Dosage for Trials | OLMA Stock News - GuruFocus
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - GlobeNewswire
FDA Green Lights Crucial Dose for Olema's Advanced Breast Cancer Drug with 2027 Launch Target - Stock Titan
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Millennium Management LLC - Defense World
Bank of America Corp DE Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Northern Trust Corp Buys 34,053 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - MSN
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Oncology Advances Cancer Trials with Strong Financials - TipRanks
Olema Oncology to Participate in Upcoming Investor Conferences | - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences | OLMA Stock News - GuruFocus
Breast Cancer Biotech Olema Sets Major Presentations at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Paradigm Biocapital Advisors LP Purchases 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by MPM Bioimpact LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $153,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
The Goldman Sachs Group Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $18.00 - Defense World
Oppenheimer Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $22.00 - Defense World
Q2 EPS Estimate for Olema Pharmaceuticals Raised by Analyst - Defense World
Voya Investment Management LLC Cuts Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Driehaus Capital Management LLC Invests $1.28 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - Yahoo Finance
Olema Pharmaceuticals (OLMA) Price Target Lowered by Oppenheimer - GuruFocus
Balyasny Asset Management L.P. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals (OLMA) Price Target Lowered by Goldman Sachs | OLMA Stock News - GuruFocus
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
올레마 주식 (OLMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Graham G. Walmsley | Director |
Dec 17 '24 |
Sale |
6.75 |
700,761 |
4,730,137 |
0 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER |
Dec 16 '24 |
Option Exercise |
4.87 |
14,000 |
68,180 |
129,509 |
2.13%
1.01%
자본화:
|
볼륨(24시간):